Audentes Therapeutics to Participate in Upcoming Investor Conferences - February 20, 2019

February 20, 2019 |

1 min read

Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced that it will participate in the following investor conferences in February and March

SAN FRANCISCO, Feb. 20, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in the following investor conferences in February and March:

8th Annual SVB Leerink Global Healthcare Conference
Natalie Holles, President and Chief Operating Officer
Format: Fireside Chat
Thursday, February 28, 2019, at 9:30 am ET
New York, New York
Cowen 39th Annual Health Care Conference
Matthew R. Patterson, Chairman and Chief Executive Officer
Format: Corporate Presentation
Tuesday, March 12, 2019, at 11:20 am ET
Boston, Massachusetts

To access live webcasts of the fireside chat and presentation, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following each conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases. We are currently conducting Phase 1/2 clinical studies of our lead product candidates, AT132 for the treatment of X-linked myotubular myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar syndrome. We have two additional product candidates in development, including AT845 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com

Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com

Audentes Therapeutics, Inc. (PRNewsfoto/Audentes Therapeutics, Inc.)